Navigation Links
CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal

LOS ANGELES--(BUSINESS WIRE)--Apr 23, 2007 - CytRx Corporation (NASDAQ:CYTR) today announced that the RNA interference (RNAi) delivery technology exclusively licensed to its majority-owned subsidiary, RXi Pharmaceuticals Corporation (RXi), has been published in the April 2007 issue of peer-reviewed scientific journal ACS Chemical Biology. The technology was developed by RXi Co-founder, Scientific Advisory Board member and University of Massachusetts Medical School (UMMS) Professor of Biochemistry and Molecular Pharmacology Tariq M. Rana, Ph.D., together with other UMMS researchers. An advance abstract of the journal article, "Design and Creation of New Nanomaterials for Therapeutic RNAi," is available online at http://pubs.acs.org/cgi-bin/abstract.cgi/acbcct/asap/abs/ cb7000582.html. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

RNAi has been shown to effectively interfere with the expression of targeted disease-associated genes with specificity and potency, and was co-discovered by 2006 Nobel Laureate Craig C. Mello, Ph.D., Co-founder of RXi and Chairman of RXi's Scientific Advisory Board. The published nanoparticle-based delivery agent enables the systemic delivery of RNAi agents in low clinically relevant doses in an animal model.

In January 2007, RXi announced that it had entered into significant agreements with UMMS to license RNAi intellectual property for all therapeutic applications. These agreements include an exclusive therapeutic license with rights to sublicense for the breakthrough nanotransporter technology.

"Delivery of intact RNAi compounds to target tissues is critical for the development of RNAi therapeutics," said Tod Woolf, Ph.D., President of RXi. "Our exclusive therapeutic rights to Dr. Rana's RNAi nanotransporter technology enhances what we believe to be RXi's competitive advantage
'"/>




Page: 1 2 3 4

Related medicine technology :

1. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
2. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:5/30/2015)... 30, 2015  Astellas Pharma Inc. (TSE: 4503) today ... on the safety, tolerability and efficacy of ASP2215, a ... refractory (R/R) acute myeloid leukemia (AML) were presented during ... Clinical Oncology,s (ASCO) annual meeting in Chicago ... kinase inhibitor of FLT3 and AXL, which are involved ...
(Date:5/30/2015)... Wash. and VANCOUVER, British Columbia ... Inc. (NASDAQ: OGXI ) announced today that results ... trial showed a benefit with custirsen therapy in men ... poor prognosis. The analysis, exploring the effect of clusterin ... that over 40 percent of men in the trial ...
(Date:5/30/2015)... y SPARTANBURG , Carolina ... - Nueva colaboración para ampliar drásticamente ... con cáncer en los Estados Unidos   ... Health proporcionarán a los pacientes con cáncer apoyo ... Guardian Research Network y Molecular Health han anunciado ...
Breaking Medicine Technology:Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) 2Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) 3OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 2OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 3OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 4OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 5OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 6Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 2Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 3Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 4
... Masimo (NASDAQ: MASI ) announced today that ... (RRa™) was presented at the New York ... Meeting in New York City. The new ... outcomes and patient safety impact of Masimo,s unique Acoustic Respiration ...
... /PRNewswire-iReach/ -- Physicians, Capital Investments, LLC (PCI/the ... and medical investment solutions is pleased to announce ... to Dallas, TX. The new headquarters, centrally located ... Company,s real estate development, business development and administrative ...
Cached Medicine Technology:New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 2New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 3New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 4New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 5Physicians' Capital Investments Announces Relocation of its Corporate Headquarters to Dallas, TX 2Physicians' Capital Investments Announces Relocation of its Corporate Headquarters to Dallas, TX 3
(Date:5/29/2015)... Displays and Exhibits’ has recently aligned with a new hanging ... signs ; making what was formerly an elite expensive ... points at a usual height of 16’-20’ are easily seen ... are very unique and more visible than the largest exhibits. ... labor and rigging the costs far outweigh the benefit of ...
(Date:5/29/2015)... 2015 Based in St. Louis, Missouri La ... for a couple of months now and are really ... which reads “I’m not misbehaving, I have Autism, please be ... of an autistic child in order to start a conversation ... only are they raising awareness through the autism awareness shirts ...
(Date:5/29/2015)... What does community do? , According to ... together to plant gardens, to teach young people, to ... critical issues. Community invites everyone to help improve lives ... Community Does" was commissioned by The Denver Foundation, the ... during the foundation’s Annual Celebration in May. At just ...
(Date:5/29/2015)... May 29, 2015 M3 USA MDLinx.com, ... in 14 medical specialties, now offers The Smartest ... spectrum of rheumatology disorders ranging from Fibromyalgia and Osteoporosis, ... editorial director of MDLinx, and Caroline Tredway, editorial head ... impact it will have on the physicians who participate. ...
(Date:5/29/2015)... Cincinnati, Ohio (PRWEB) May 29, 2015 ... Proven Experience to Cincinnati , The Department of Veterans ... John A. Gennaro as the new director of the ... of health care to more than 43,000 unique Veterans ... , With over 2,000 staff, CVAMC is a two-division ...
Breaking Medicine News(10 mins):Health News:Displays and Exhibits Announces New Hanging Sign Supplier 2Health News:La La Land Shirts Is Busy Spreading Autism Awareness with Complimentary Shipping on Their New Shirt 2Health News:What Community Does: A New Video from The Denver Foundation 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:VA Healthcare System of Ohio Network Announces New Medical Center Director 2
... ... promotes Prize4Life. , ... (Vocus) March 24, 2010 -- In April of 2009, Director/Producer James Takata, Writers/Producers Zach ... Prize4Life’s battle against ALS. Trapped is a short film about Stephen, a talented young ...
... in Spanish . Barcelona, Spain: Recurrence ... tumour remains the strongest, independent prognostic factor for subsequent metastasis ... disease for a very long time, according to research presented ... Dr Sven Mieog, MD, a research fellow at Leiden ...
... release is available in Spanish . ... women are surviving breast cancer and delaying childbirth, it is ... fertility into consideration when deciding on treatment, the seventh European ... Dr. Anne Armstrong, from the Department of Medical Oncology, the ...
... after the death of a loved one can provide much-needed ... a study in the April issue of the Journal ... lost a relative to cancer took part in the study. ... included widows, widowers, daughters and sisters. Nine chose foot massage, ...
... Organic Relaxation Herbal ... the product works. This Herbal Tea can be purchased at Youmeandtea.com, , , ... (PRWEB) March 24, 2010 -- Organic Relaxation ... well the product works. This Herbal Tea can be purchased at Youmeandtea.com , ,"I ...
... ... obesity and empower kids to make healthy decisions. , ... (Vocus) March 24, 2010 -- To help kids to make healthy ... www.mvpkidpower.com on Facebook., , , , ,“Being on Facebook enables KidPower to actually ...
Cached Medicine News:Health News:Prize4Life Inspires Award-winning ALS Film: Trapped 2Health News:Prize4Life Inspires Award-winning ALS Film: Trapped 3Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 3Health News:Fertility issues in young women with breast cancer must be addressed 2Health News:Hand and feet massages provide consolation for bereaved relatives 2Health News:Snoring Reduced With Relaxation Tea… Could It Be? 2Health News:Snoring Reduced With Relaxation Tea… Could It Be? 3Health News:MVP Health Care Takes KidPower Youth Sports Program to Facebook 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: